Familial adenomatous polyposis (FAP)
PBLSParbaillis MedicinesCatalyst overview
Research summary
This catalyst tracks a Phase 1/2 data readout for Zolucatetide (FOG-001) in Familial adenomatous polyposis (FAP). The expected timing is based on the latest available company guidance and may change.
03/05/26:- Zolucatetide showed early evidence of reduced duodenal polyp burden in a FAP patient from ongoing Ph1/2 trial; additional readouts expected in 2026. 08/13/26:- Dedicated FAP cohort enrollment will begin in H2 2026. Additional FAP data are expected in Q1 2027.
Verification
Confirm timing and program details against the company announcement or filing.